Alendronic acid (Acidum alendronicum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Correctors of bone and cartilage tissue metabolism

Included in the formulation
  • Alendercourne
    pills inwards 
    Kern Pharma S.L.     Spain
  • Alendronate
    pills inwards 
    VERTEKS, AO     Russia
  • Alendronate
    pills inwards 
    Berezovsky Pharmaceutical Plant, ZAO     Russia
  • Alendronate
    pills inwards 
    CANONFARMA PRODUCTION, CJSC     Russia
  • Alendronate Pliva
    pills inwards 
    Pliva of Hrvatska doo     Croatia
  • Binosto
    pills inwards 
    Polypharm, LLC     Russia
  • Ostalon®
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Osterepar®
    pills inwards 
    Pharmaceutical factory "POLFARMA" JSC     Poland
  • Strongos
    pills inwards 
    VEROPHARM SA     Russia
  • Tevanat®
    pills inwards 
    Teva Pharmaceutical Enterprises Co., Ltd.     Israel
  • Forosa®
    pills inwards 
    Lek dd     Slovenia
  • Fosamax®
    pills inwards 
    Merck Sharp and Doum B.V.     Netherlands
    • Included in the list (Order of the Government of the Russian Federation No. 2782-r of 30.12.2014):

    VED

    АТХ:

    M.05.B.A.04   Alendronic acid

    Pharmacodynamics:

    Refers to the group of bisphosphonates, inhibits bone resorption in malignant tumors and bone metastases. It suppresses the activity of osteoclasts, causes damage to their structure, decreases in size and quantity.

    Selectively affects the bone tissue. Reduces the severity of pain in osteoporosis and metastatic bone damage.Effectively reduces the level of calcium in the blood plasma, preventing the development of clinical signs of hypercalcemia and hypercalcaemic coma.

    In the treatment of osteoporosis, the mass of bone tissue increases by the end of the first year of therapy, especially in the spine. As an alternative to hormone replacement therapy can be used in postmenopausal osteoporosis. When an overdose affects osteoblasts, and the mineralization of bone tissue (osteomalacia) is disturbed.

    Pharmacokinetics:

    After oral administration, an empty stomach is absorbed up to 25% in the gastrointestinal tract. After intravenous administration, it is distributed in an equilibrium state, followed by deposition in bone and cartilage tissue. The connection with plasma proteins is 78%.

    Not exposed to metabolism.

    The half-life of plasma is 6 hours, of bone tissue - more than 10 years. Elimination by the kidneys and with feces.

    Indications:

    It is used for the treatment of Paget's disease and in osteoporosis: in postmenopause, in order to prevent fractures in men, due to prolonged use of glucocorticosteroids.

    ICD-10

    XIII.M80-M85.M80   Osteoporosis with pathological fracture

    XIII.M80-M85.M81.1   Osteoporosis after removal of ovaries

    XIII.M80-M85.M81.0   Postmenopausal osteoporosis

    XIII.M86-M90.M89.5   Osteolysis

    XIII.M80-M85.M81.4   Medicinal osteoporosis

    Contraindications:

    Chronic renal failure, vitamin D deficiency, abnormalities and pathologies of the gastrointestinal tract, accompanied by obstruction of the esophagus, individual intolerance, children under 18 years of age.

    Carefully:

    Hypovitaminosis D, diseases of the gastrointestinal tract: dysphagia, gastritis, duodenitis, peptic ulcer in the acute stage, active gastrointestinal bleeding or surgical operation on the upper divisions gastrointestinal tract in the anamnesis.

    Pregnancy and lactation:

    Recommendations for FDA - category D. Contraindicated in pregnancy and lactation.

    Dosing and Administration:

    Inside for 70 mg once a week, on an empty stomach 2 hours before the first meal.

    The highest daily dose: 70 mg.

    The highest single dose: 70 mg.

    Side effects:

    Central and peripheral nervous system: headache, dizziness, agitation, insomnia or drowsiness, impaired orientation, convulsions, visual hallucinations.

    Hemopoietic system: anemia, leukopenia, thrombocythemia.

    The cardiovascular system: exacerbation of heart disease, increase or decrease in blood pressure.

    Digestive system: anorexia, abdominal pain, dyspepsia, rarely gastritis.

    Musculoskeletal system: pain in the lower back, in the bones, myalgia, arthralgia.

    Sense organs: conjunctivitis, scleritis, rarely xantopsy.

    urinary system: development of acute renal failure, hematuria, urinary tract infection.

    Allergic reactions.

    Overdose:

    Hypocalcemia: arterial hypotension, tetany, paresthesia.

    Treatment: intravenous administration of calcium gluconate.

    Interaction:

    Simultaneous use of aminoglycosides increases the risk of hypocalcemia.

    Drugs containing divalent cations (Ca, Fe, Mn, Mg, etc.), easily form bonds with alendronic acid, so such drugs can not simultaneously take inside.

    Ranitidine improves bioavailability.

    Mineral water and juices degrade the absorption of the drug.

    Nonsteroidal anti-inflammatory drugs increase side effects.

    Special instructions:

    To avoid irritation of the mucosa of the esophagus, it is recommended to take the tablet with ordinary water in an amount of not less than 200 ml and Do not take the horizontal position of the body.

    During treatment, you need to consume enough fluids and restrict the intake of foods that contain calcium.

    Instructions
    Up